Lantheus Shares Trading Higher On FDA Approval For Imaging Agent For Identification Of Prostate Cancer

The FDA has approved Lantheus Holdings Inc's LNTH Pylarify, a positron emission tomography (PET) imaging agent, to identify suspected metastasis or recurrence of prostate cancer.
Pylarify is an F 18-labeled prostate-specific membrane antigen (PSMA) imaging agent for diagnosing prostate cancer. It is the first and only commercially available approved PSMA PET imaging agent for prostate cancer, said the company.
The product will be immediately available in parts of the mid-Atlantic and southern regions, and availability is expected to expand over the next six months, with broad availability across the U.S. anticipated by the end of 2021.
Pylarify was developed to target PSMA, a protein overexpressed on the surface of more than 90% of primary and metastatic prostate cancer cells.
It binds to the target, enabling the reader of the PET scan to detect and locate the disease.
Price Action: LNTH shares are up 15.3% at $22.49 during the premarket session on the last check Thursday.